Andrew I. Flyak

2.8k total citations
30 papers, 1.4k citations indexed

About

Andrew I. Flyak is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Andrew I. Flyak has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 15 papers in Epidemiology and 12 papers in Hepatology. Recurrent topics in Andrew I. Flyak's work include Viral Infections and Outbreaks Research (14 papers), Hepatitis C virus research (12 papers) and Hepatitis B Virus Studies (11 papers). Andrew I. Flyak is often cited by papers focused on Viral Infections and Outbreaks Research (14 papers), Hepatitis C virus research (12 papers) and Hepatitis B Virus Studies (11 papers). Andrew I. Flyak collaborates with scholars based in United States, Bahrain and Germany. Andrew I. Flyak's co-authors include James E. Crowe, Justin R. Bailey, Erica Ollmann Saphire, Marnie L. Fusco, Zachary A. Bornholdt, Philipp A. Ilinykh, Alexander Bukreyev, Stuart C. Ray, Pamela J. Björkman and Benjamin J. Doranz and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Andrew I. Flyak

29 papers receiving 1.4k citations

Peers

Countries citing papers authored by Andrew I. Flyak

Since Specialization

Citations

This map shows the geographic impact of Andrew I. Flyak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew I. Flyak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew I. Flyak more than expected).

Fields of papers citing papers by Andrew I. Flyak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew I. Flyak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew I. Flyak. The network helps show where Andrew I. Flyak may publish in the future.

Co-authorship network of co-authors of Andrew I. Flyak

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew I. Flyak. A scholar is included among the top collaborators of Andrew I. Flyak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew I. Flyak. Andrew I. Flyak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structures and functions of the limited natural polyclonal antibody response to parvovirus infection 2025 ·Proceedings of the National Academy of Sciences ·(unknown), Hyunwook Lee, (unknown), (unknown), Wendy S. Weichert, Andrew I. Flyak, Susan Hafenstein, Colin R. Parrish	0
2	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection 2022 ·PLoS Pathogens ·(unknown), Nicole Skinner, Andrew I. Flyak, (unknown), (unknown), Pamela J. Björkman, James E. Crowe, Andrea L. Cox, Stuart C. Ray, Justin R. Bailey	6
3	Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals 2022 ·Nature Communications ·Nina G. Bozhanova, Andrew I. Flyak, Benjamin P. Brown, (unknown), (unknown), Semi Rho, Robin Bombardi, Luke Myers, Cinque Soto, Justin R. Bailey, James E. Crowe, Pamela J. Björkman, Jens Meiler	5
4	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency 2022 ·Journal of Clinical Investigation ·(unknown), (unknown), (unknown), Muhammad Zahid, Shuyi Wang, Guido Massaccesi, (unknown), James E. Crowe, Andrew I. Flyak, Hongkai Ji, Stuart C. Ray, George M. Shaw, Andrea L. Cox, Justin R. Bailey	9
5	Mechanisms of HCV resistance to broadly neutralizing antibodies 2021 ·Current Opinion in Virology ·(unknown), Andrew I. Flyak, Justin R. Bailey	5
6	Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies 2021 ·Cell Reports ·Charles D. Murin, Pavlo Gilchuk, Philipp A. Ilinykh, Kai Huang, Natalia A. Kuzmina, Xiaoli Shen, Jessica F. Bruhn, Aubrey L. Bryan, Edgar Davidson, Benjamin J. Doranz, Lauren E. Williamson, Jeffrey Copps, (unknown), Andrew I. Flyak, Alexander Bukreyev, James E. Crowe, Andrew B. Ward	19
7	An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein 2020 ·eLife ·Andrew I. Flyak, (unknown), (unknown), Semi Rho, Justin R. Bailey, Pamela J. Björkman	21
8	Nur77 controls tolerance induction, terminal differentiation, and effector functions in semi-invariant natural killer T cells 2020 ·Proceedings of the National Academy of Sciences ·Amrendra Kumar, Timothy Hill, Laura E. Gordy, Naveenchandra Suryadevara, Lan Wu, Andrew I. Flyak, Jelena S. Bezbradica, Luc Van Kaer, Sebastian Joyce	15
9	Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance 2019 ·Journal of Clinical Investigation ·(unknown), Guido Massaccesi, Andrew I. Flyak, Madeleine C. Mankowski, (unknown), William O. Osburn, Stuart C. Ray, Andrea L. Cox, James E. Crowe, Justin R. Bailey	36
10	Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2 2019 ·Journal of Virology ·(unknown), Andrew I. Flyak, (unknown), (unknown), Guido Massaccesi, (unknown), Edgar Davidson, Benjamin J. Doranz, Andrea L. Cox, James E. Crowe, Justin R. Bailey	35
11	Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors 2018 ·Cell Reports ·Natalia A. Kuzmina, Patrick Younan, Pavlo Gilchuk, Rodrigo I. Santos, Andrew I. Flyak, Philipp A. Ilinykh, Kai Huang, Ndongala Michel Lubaki, Palaniappan Ramanathan, James E. Crowe, Alexander Bukreyev	55
12	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design 2018 ·Cell Host & Microbe ·Andrew I. Flyak, (unknown), (unknown), Tiffany Luong, James E. Crowe, Justin R. Bailey, Pamela J. Björkman	85
13	Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap 2018 ·PLoS Pathogens ·Philipp A. Ilinykh, Rodrigo I. Santos, Bronwyn M. Gunn, Natalia A. Kuzmina, Xiaoli Shen, Kai Huang, Pavlo Gilchuk, Andrew I. Flyak, Patrick Younan, Galit Alter, James E. Crowe, Alexander Bukreyev	14
14	Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody 2017 ·Science Translational Medicine ·Chad E. Mire, Joan B. Geisbert, Viktoriya Borisevich, Karla A. Fenton, Krystle N. Agans, Andrew I. Flyak, Daniel J. Deer, Herta Steinkellner, Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, (unknown), Michael Pauly, Jesús Velasco, Kevin J. Whaley, James E. Crowe, Larry Zeitlin, Thomas W. Geisbert	69
15	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance 2017 ·JCI Insight ·Justin R. Bailey, Andrew I. Flyak, (unknown), Hui Li, Lisa N. Wasilewski, Anna E. Snider, Shuyi Wang, Gerald H. Learn, Nurgun Kose, (unknown), Rebecca Lampley, Andrea L. Cox, Jennifer M. Pfaff, Benjamin J. Doranz, George M. Shaw, Stuart C. Ray, James E. Crowe	95
16	A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses 2016 ·Science ·Anna Z. Wec, Elisabeth K. Nyakatura, Andrew S. Herbert, Katie A. Howell, Frederick W. Holtsberg, Russell R. Bakken, Eva Mittler, John R. Christin, Sergey Shulenin, Rohit K. Jangra, Sushma Bharrhan, Ana I. Kuehne, Zachary A. Bornholdt, Andrew I. Flyak, Erica Ollmann Saphire, James E. Crowe, M. Javad Aman, John M. Dye, Jonathan R. Lai, Kartik Chandran	80
17	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies 2016 ·Nature Microbiology ·Jesper Pallesen, Charles D. Murin, Natalia de Val, Christopher A. Cottrell, Kathryn M. Hastie, Hannah L. Turner, Marnie L. Fusco, Andrew I. Flyak, Larry Zeitlin, James E. Crowe, Kristian G. Andersen, Erica Ollmann Saphire, Andrew B. Ward	87
18	Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody 2015 ·Cell ·Takao Hashiguchi, Marnie L. Fusco, Zachary A. Bornholdt, Jeffrey E. Lee, Andrew I. Flyak, Rei Matsuoka, Daisuke Kohda, Yusuke Yanagi, Michal Hammel, James E. Crowe, Erica Ollmann Saphire	103
19	Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus 2015 ·Cell Host & Microbe ·Scott A. Smith, Laurie A. Silva, Julie M. Fox, Andrew I. Flyak, Nurgun Kose, Gopal Sapparapu, Solomiia Khomandiak, Alison W. Ashbrook, Kristen M. Kahle, Rachel H. Fong, (unknown), Benjamin J. Doranz, Charles E. McGee, Mark T. Heise, Pankaj Pal, James D. Brien, (unknown), Michael Diamond, (unknown), James E. Crowe	106
20	Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus 2015 ·Cell ·Andrew I. Flyak, Philipp A. Ilinykh, Charles D. Murin, Tania Garron, Xiaoli Shen, Marnie L. Fusco, Takao Hashiguchi, Zachary A. Bornholdt, James C. Slaughter, Gopal Sapparapu, (unknown), Thomas G. Ksiazek, Andrew B. Ward, Erica Ollmann Saphire, Alexander Bukreyev, James E. Crowe	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact